Ex-US FDA official to lead Hong Kong’s new medical products regulator

The establishment of the CMPR is part of a broader regulatory overhaul aimed at accelerating the clinical application of medicines and medical devices. The new body will promote proactive "primary evaluation" to ensure patients have access to state-of-the-art medical products that meet quality and safety standards.

According to Dr Ronald Lam, Director of Health, the reform aligns with Hong Kong's First Five-Year Plan for Economic and Social Development (2026-2030) and the Chief Executive's 2026 Policy Address. The initiative seeks to enhance Hong Kong's regulatory regime to international standards, develop independent evaluation and approval capabilities, and position the city as an international health and medical innovation hub. This effort also aims to dovetail with China's strategic development in biomedicine and medical devices, contributing to the national "Healthy China" strategy.